[{"abstract": "In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.", "web_url": "https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash/", "snippet": "In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.", "lead_paragraph": "Pfizer is making a $15.2 billion bet on the drug industry\u2019s new, more elite class of generics: costly, complex copies of already expensive biotech drugs.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg", "height": 415, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 415}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/06DRUG/06DRUG-jumbo.jpg", "height": 708, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/06DRUG/06DRUG-superJumbo.jpg", "height": 1417, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/06DRUG/06DRUG-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Bets $15 Billion on New Class of Generic Drugs", "kicker": "DealBook", "content_kicker": null, "print_headline": "Pfizer Bets $15 Billion on New Sort of Generics", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Generic Brands and Products", "rank": 4, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Hospira Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 7, "major": "N"}], "pub_date": "2015-02-05T12:24:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By David Gelles and Katie Thomas", "person": [{"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/57e135c7-12dd-5648-bf61-1c5c50c8908a", "word_count": 1188, "uri": "nyt://article/57e135c7-12dd-5648-bf61-1c5c50c8908a"}, {"abstract": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2015/02/05/a-deal-that-could-reverse-pfizers-history-of-value-destroying-acquisitions/", "snippet": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "lead_paragraph": "Pfizer has made more than its share of value-destroying acquisitions. The pharmaceutical giant\u2019s $15.2 billion purchase of Hospira could reverse that history. The injectable-drug maker\u2019s strength in non-branded medications should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg", "height": 800, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 800}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-jumbo.jpg", "height": 1024, "width": 768, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-superJumbo.jpg", "height": 2048, "width": 1536, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "A Deal That Could Reverse Pfizer\u2019s History of Value-Destroying Acquisitions", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Hospira Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Warner-Lambert Co", "rank": 7, "major": "N"}], "pub_date": "2015-02-05T19:10:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc", "word_count": 383, "uri": "nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc"}, {"abstract": "In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE.", "web_url": "https://dealbook.nytimes.com/2015/02/05/pfizer-deal-and-other-mergers-show-a-case-of-the-mondays-on-a-thursday/", "snippet": "In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE.", "lead_paragraph": "Wall Street has a late-in-the-week case of the Mondays.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg", "height": 435, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 435}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-jumbo.jpg", "height": 743, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-superJumbo.jpg", "height": 1486, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Deal and Other Mergers Show a Case of the Mondays, on a Thursday", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Ball Corporation", "rank": 2, "major": "N"}, {"name": "organizations", "value": "BT Group PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "EE Ltd", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Hospira Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}], "pub_date": "2015-02-05T19:12:34+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By William Alden", "person": [{"firstname": "William", "middlename": null, "lastname": "Alden", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98", "word_count": 351, "uri": "nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98"}]